Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon‐α treatment in HBeAg‐positive chronic hepatitis B patients

Serum Mac‐2‐binding protein glycosylation isomer (M2BPGi) level was found to be a useful prognostic marker for hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB) patients treated with nucleoside/nucleotide analogs (NUCs) therapy, and the aim of our study is to evaluate the clinical imp...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Zhu, Ming‐Yu, Chen, Pei‐Zhan, Li, Jing, Yu, De‐Min, Huang, Dao, Zhu, Xue‐Juan, Han, Yue, Chen, Jie, Huang, Wei, Chen, Yong‐Yan, Gong, Qi‐Ming, Jiang, Jie‐Hong, Zhang, Dong‐Hua, Zhang, Yan, Zhang, Ji‐Ming, Zhang, Xin‐Xin
Format: Online Artykuł Texto
Język:English
Wydane: John Wiley and Sons Inc. 2018
Hasła przedmiotowe:
Research Articles
Dostęp online:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838532/
https://www.ncbi.nlm.nih.gov/pubmed/29247529
http://dx.doi.org/10.1002/jmv.25010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838532/
https://www.ncbi.nlm.nih.gov/pubmed/29247529
http://dx.doi.org/10.1002/jmv.25010

Podobne zapisy